Generic Injectables Market Growth, Key Futuristic Trends and Competitive Landscape 2023-2028


Generic Injectables Market delivers a comprehensive study of the market, including its dynamics, structure, characteristics, key players, growth and demand drivers, etc. As a complete analysis report, it covers all details inside analysis and outlook according to the insight partners

An exclusive Generic Injectables Market research report provides depth analysis of the market dynamics across five regions such as North America, Europe, South America, Asia-Pacific, Middle East and Africa.

According to our new research study on Generic Injectables Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by product type, container type, application, and route of administration,” the generic injectables market size is expected to grow from US$ 74.74 billion in 2021 to US$ 150.65 billion by 2028; it is estimated to grow at a CAGR of 10.5% during 2021–2028. The generic injectables market growth is attributed to low R&D, marketing, and manufacturing costs, and the rising prevalence of chronic illness cases are expected to drive the growth of the market.

North America held the significant market share in generic injectables market. The growth of the market in countries such as the US and Canada is driven by the factors such as increasing demand for generic injectables to lower the treatment cost and growing support through an initiative to enhance generic pharmaceutical production.


The prominent/emerging players in the Generic Injectables Market research include:

  • Astrazeneca
  • Baxter International, Inc.
  • Biocon
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin, Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer, Inc.

Generic injectables are affordable and provide greater access to healthcare. For instance, as published by the Association for Accessible Medicines (AAM), the average primary copay (the amount set by the insurance plans) of a generic drug is US$ 6.06 and US$ 40.30 for branded drugs. This fact indicates the falling prices of generic medicines by at least ~7%. Additionally, according to the American Association of Retired Person (AARP), branded drug prices continue to increase at a pace that is 100-times greater than inflation. The high acceptance of generic injectables by patients due to low prices and easy accessibility, pushing physicians to prescribe generic version of medicines. For instance, as mentioned by the USFDA, 9/10 prescriptions filled in the US are for generic drugs.

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
Phone: +1-646-491-9876